ABPI response to Journal of Royal Society of Medicine report on Innovative Medicines Fund
ABPI response to Journal of Royal Society of Medicine report on Innovative Medicines Fund
The Journal of the Royal Society of Medicine has issued a report highlighting concerns about the Innovative Medicines Fund.
The Innovative Medicines Fund was introduced in June 2022.
In response to the concerns, ABPI Director of Value and Access Policy Paul Catchpole said:
“The Cancer Drugs Fund has allowed tens of thousands of NHS patients earlier access to cancer drugs deemed by NICE to potentially be value for money, but which need more evidence before entering routine commissioning.
“The Innovative Medicines Fund was introduced more than a year ago to allow patients with other diseases, including rare conditions, to benefit from similar managed access to new medicines, while additional evidence is collected.
"No medicines have yet entered the fund on this basis, and we would like to work with NHS England and NICE to better understand why and help bring the fund to life so that patients can benefit.”
Editor Details
-
Company:
- PharmiWeb.com
-
Name:
- PW Editor
- Email:
-
Telephone:
- +441344851506
